Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes.

GLP-1 receptor agonists may aid smoking cessation by curbing cravings and mitigating weight gain, which often are impediments ...

For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric adverse events or worsening ...

GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes compared with dipeptidyl ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation ...

Get Instant Summarized Text (Gist) First-generation GLP-1 receptor agonists reduce the risk of obesity-related cancers independently of weight loss, showing a 41% lower relative risk compared to ...

There were associations for GLP-1 RA treatment vs placebo with improvements in restrained eating and emotional eating behavior and in mental health-related QOL. HealthDay News — For patients ...

GLP-1 receptor agonists are associated with improvements in restrained eating, emotional eating behavior, QOL. (HealthDay News) — For patients with overweight/obesity and/or diabetes ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), a class of drugs commonly prescribed for type 2 diabetes, improve cardiovascular outcomes such as heart failure (HF), acute myocardial ...

As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights ...